Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.

European journal of cancer (Oxford, England : 1990) - 1 Oct 2014

Barbour Andrew P, Tang Yue Hang, Armour Nicola, Dutton-Regester Ken, Krause Lutz, Loffler Kelly A, Lambie Duncan, Burmeister Bryan, Thomas Janine, Smithers B Mark, Hayward Nicholas K

Abstract excerpt

BACKGROUND: 5-year survival for melanoma metastasis to regional lymph nodes (American Joint Committee on Cancer stage III) is <50%. Knowledge of outcomes following therapeutic lymphadenectomy for stage III melanoma related to BRAF status may guide adjuvant use of BRAF/MEK inhibitors along with established and future therapies. AIMS: To determine patterns of melanoma recurrence and survival following therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy
Share to Lymph Node Excision

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphatic Metastasis

Share to Neoplasm Recurrence, Local

Share to Outcome Assessment, Health Care

Share to Proportional Hazards Models

Share to Proto-Oncogene Mas

Share to Radiotherapy, Adjuvant

Source

Identifiers

PMID: 25070294
DOI: 10.1016/j.ejca.2014.06.009

Genes

BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.PMID 25070294Read ↗

Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.Semantic proximity Read ↗

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.Semantic proximity Read ↗

Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection.Semantic proximity Read ↗

Association of BRAF Mutation Status with Histopathological Characteristics and Survival Outcomes in Stage II-III Malignant Melanoma.Semantic proximity Read ↗

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.Semantic proximity Read ↗

The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.Semantic proximity Read ↗

BRAF Mutation Correlates with Worse Local-regional Control Following Radiation Therapy in Patients with Stage III MelanomaSemantic proximity Read ↗

BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma.Semantic proximity Read ↗

Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy.Semantic proximity Read ↗

NRAS mutation status is an independent prognostic factor in metastatic melanoma.Semantic proximity Read ↗

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.Semantic proximity Read ↗

Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary MelanomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.